Название продукции:(R)-6-tert-Butyl 4a-methyl 1-(4-fluorophenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isoquinoline-4a,6(4H)-dicarboxylate
IUPAC Name:6-tert-butyl 4a-methyl (4aR)-1-(4-fluorophenyl)-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a,6-dicarboxylate
- CAS:864972-21-4
- Молекулярная формула:C23H26FN3O4
- Чистота:97%
- Номер в каталоге:CM227405
- Молекулярная масса:427.48
Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:864972-21-4
- Молекулярная формула:C23H26FN3O4
- Точка плавления:-
- Smiles-код:O=C([C@]12CC3=C(N(C4=CC=C(F)C=C4)N=C3)C=C1CCN(C(OC(C)(C)C)=O)C2)OC
- Плотность:
- Номер в каталоге:CM227405
- Молекулярная масса:427.48
- Точка кипения:
- Номер Mdl:
- Хранение:
Column Infos
- Relacorilant
- Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.